[{"orgOrder":0,"company":"Solventum","sponsor":"Cyberderm Inc. | 3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ Cyberderm Inc. | 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ Cyberderm Inc. | 3M Company"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Solventum","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Solventum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solventum \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Solventum \/ 3M Company"},{"orgOrder":0,"company":"Universitat Internacional de Catalunya","sponsor":"Dentaid","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Universitat Internacional de Catalunya","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitat Internacional de Catalunya \/ Dentaid","highestDevelopmentStatusID":"8","companyTruncated":"Universitat Internacional de Catalunya \/ Dentaid"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Queen Mary University of London \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Lindenhofgruppe AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Lindenhofgruppe AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lindenhofgruppe AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lindenhofgruppe AG \/ Undisclosed"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ Undisclosed"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"BioScience Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ BioScience Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ BioScience Laboratories"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"BioScience Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ BioScience Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ BioScience Laboratories"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Hospital and Medical Center, Phoenix","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"St. Joseph's Hospital and Medical Center, Phoenix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"St. Joseph's Hospital and Medical Center, Phoenix \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Hospital and Medical Center, Phoenix \/ 3M Company"},{"orgOrder":0,"company":"CareFusion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"CareFusion","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareFusion \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CareFusion \/ Undisclosed"},{"orgOrder":0,"company":"CareFusion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"CareFusion","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareFusion \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CareFusion \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de Guanajuato","sponsor":"Antisepsia Central","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Universidad de Guanajuato","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de Guanajuato \/ Antisepsia Central","highestDevelopmentStatusID":"10","companyTruncated":"Universidad de Guanajuato \/ Antisepsia Central"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Metro Health, Michigan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Metro Health, Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metro Health, Michigan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Metro Health, Michigan \/ Undisclosed"},{"orgOrder":0,"company":"The Cooper Health System","sponsor":"University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Cooper Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Cooper Health System \/ University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network","highestDevelopmentStatusID":"10","companyTruncated":"The Cooper Health System \/ University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network"},{"orgOrder":0,"company":"State University of New York at Buffalo","sponsor":"SUNSTAR AMERICAS INC","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Endocrinology","graph2":"Phase II","graph3":"State University of New York at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"State University of New York at Buffalo \/ SUNSTAR AMERICAS INC","highestDevelopmentStatusID":"8","companyTruncated":"State University of New York at Buffalo \/ SUNSTAR AMERICAS INC"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ 3M Company"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University \/ Stryker","highestDevelopmentStatusID":"10","companyTruncated":"Vanderbilt University \/ Stryker"},{"orgOrder":0,"company":"3M Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase III","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"3M Company \/ Undisclosed"},{"orgOrder":0,"company":"Zurex Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zurex Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zurex Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zurex Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zurex Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zurex Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zurex Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zurex Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Angela Bianco","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Angela Bianco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angela Bianco \/ Stryker","highestDevelopmentStatusID":"8","companyTruncated":"Angela Bianco \/ Stryker"},{"orgOrder":0,"company":"Caroline Scott","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Caroline Scott","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caroline Scott \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Caroline Scott \/ Undisclosed"},{"orgOrder":0,"company":"Joseph Kim","sponsor":"Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Joseph Kim","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Kim \/ Alberta Health services","highestDevelopmentStatusID":"1","companyTruncated":"Joseph Kim \/ Alberta Health services"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Guanylate cyclase (GC)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ondine Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Healthcare's Memorial Health University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Guanylate cyclase (GC)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center"}]
Find Clinical Drug Pipeline Developments & Deals for PREVANTICS SWABSTICK
Sponsor :
University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network
Details :
Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Surgical Wound Infection.
Sponsor :
University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network
Details :
Nasal antimicrobial photodisinfection therapy consisiting of NF-031 (methylthioninium chloride & chlorhexidine gluconate) is being evaluated for treatment of surgical site infections.
Details :
Chlorhexidine Digluconate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Gingivitis.
Details :
Photodynamic Antimicrobial Chemotherapy (PACT) using methylene blue is a potential antimicrobial therapy that combines light and a photosensitizing drug, promoting a phototoxic effect on the treated cells increases membrane permeability in Candida albica...
Details :
Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Details :
Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Details :
Corsodyl (Chlorhexidine Digluconate) is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Details :
Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Reset All
